Results 161 to 170 of about 22,921 (208)

Fixed-duration cytarabine consolidation improves relapse-free survival over indefinite AZA-VEN in younger AML. [PDF]

Blood Cancer J
Swain RN, Jain A, Wadhera S, Singh C, Jandial A, Khadwal A, Sachdeva MU, Naseem S, Malhotra P, Prakash G.   +9 more
europepmc   +1 more source

Treatment of Acute Myeloid Leukemia in Elderly Patients With Azacitidine-Venetoclax Combination in Developing Countries: A Single-Center Experience. [PDF]

Cureus
Chakara R, Mohamed Amine A, Raissi A.
europepmc   +1 more source

Local Promoter Methylation Disorder algorithm reveals bidirectional epigenetic disruption in DNMT3A-mutated AML and predicts azacitidine treatment response. [PDF]

Front Oncol
Liu X, Cheng S, Lin B, Cui M.
europepmc   +1 more source

Quantitative Stability Evaluation of Reconstituted Azacitidine Under Clinical Storage Conditions. [PDF]

Pharmaceuticals (Basel)
Ruga S, Lombardi R, Bocci T, Armenise M, Masullo M, Lamesta C, Bava R, Castagna F, Matarese E, Di Viesti MP, Biancofiore A, Liguori G, Palma E.   +12 more
europepmc   +1 more source

Toward therapeutic development for ML-DS. [PDF]

Blood Adv
Tomizawa D.
europepmc   +1 more source

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. [PDF]

Blood Adv
Montesinos P, Marchione DM, Recher C, Heuser M, Vives S, Zarzycka E, Wang J, Riva M, Calado RT, Schuh AC, Yeh SP, Tron AE, Hui J, Gianolio DA, Choe S, Patel P, De Botton S, DiNardo CD, Döhner H.   +18 more
europepmc   +1 more source

Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives. [PDF]

Oncol Res
Chen T, Kim G, Rahimi Y, Kamdar M, Fernandez-Hernandez E, Woan K, Tam EL, Yaghmour G.   +7 more
europepmc   +1 more source

The role of m6A RNA methyltransferase METTL3 in drug resistance mechanisms in acute myeloid leukemia. [PDF]

Blood Res
Prajapati S, Jyotishi C, Patel M, Gupta R.   +3 more
europepmc   +1 more source